SCHEMBL295233

SCHEMBL295233

Cc1cc2ccccc2c(=O)o1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGES O14684 3/20 0.56
TYMP P19971 1/20 0.54
MAOA P21397 1/20 0.53
KDM4E B2RXH2 3/20 0.50
ALDH1A1 P00352 3/20 0.50
MAPT P10636 2/20 0.50
CASP3 P42574 1/20 0.50
SENP7 Q9BQF6 1/20 0.50
MITF O75030 1/20 0.50
HPGD P15428 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
ELANE P08246 2/20 0.49
ALOX5 P09917 3/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C19 P33261 1/20 0.47
TP53 P04637 1/20 0.46
GAA P10253 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31604207 1.00 PTGES (0.56) PTGESTYMPMAOAKDM4EALDH1A1
SCHEMBL19583424 0.78 PTGES (0.78) PTGESTYMPKDM4EALDH1A1MAPT
SCHEMBL19793345 0.78 ELANE (0.53) MAOAKDM4EALDH1A1MAPTELANE
SCHEMBL27845272 0.78 ELANE (0.49) MAOAKDM4EALDH1A1MAPTELANE
SCHEMBL6449120 0.75 PTGES (0.56) PTGESTYMPKDM4EALDH1A1MAPT
SCHEMBL28549436 0.75 PTGES (0.56) PTGESTYMPKDM4EALDH1A1MAPT
SCHEMBL3000739 0.75 MITF (0.59) PTGESTYMPKDM4EALDH1A1MAPT
SCHEMBL1649762 0.75 PTGES (0.56) PTGESTYMPKDM4EALDH1A1MAPT
SCHEMBL21058262 0.75 PTGES (0.56) PTGESTYMPKDM4EALDH1A1MAPT
SCHEMBL31661103 0.75 PTGES (0.56) PTGESTYMPKDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11814669-B2 Blood sample assay method Abbott Rapid Diagnostics International Unlimited Company (IE) 2023-11-14 US disclosed
US-20210332410-A1 BLOOD SAMPLE ASSAY METHOD Abbott Rapid Diagnostics International Unlimited Company (IE) 2021-10-28 US disclosed
US-11085066-B2 Blood sample assay method AXIS-SHIELD AS (NO) 2021-08-10 US disclosed
US-20200131560-A1 BLOOD SAMPLE ASSAY METHOD Abbott Rapid Diagnostics International Unlimited Company (IE) 2020-04-30 US disclosed
EP-3122735-B1 3-PHENYL-7-HYDROXY-ISOCOUMARINS AS MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) INHIBITORS THE PROVOST FELLOWS FOUND SCHOLARS AND THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIV (IE) 2019-05-08 EP disclosed
US-20190071410-A1 3-Phenyl-7-Hydroxy-Isocoumarins as Macrophage Migration Inhibitory Factor (MIF) Inhibitors THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) 2019-03-07 US disclosed
EP-3435089-A1 DETERMINATION OF NON-HDL CHOLESTEROL IN BLOOD Axis-Shield AS (NO) 2019-01-30 EP disclosed
CN-108947900-A The method of carbon arylation tandem reaction synthesizing heterocyclic compound of the photoinduction without metal catalytic 河南大学 2018-12-07 CN disclosed
EP-2751575-B1 BLOOD SAMPLE ASSAY METHOD AXIS SHIELD AS (NO) 2018-09-12 EP disclosed
US-10043981-B2 Light-emitting material, organic light-emitting device, and compound KYULUX, INC. (JP) 2018-08-07 US disclosed
EP-2235543-A1 METHOD TO DETERMINE LIPIDS Axis-Shield Asa (NO) 2010-10-06 EP disclosed
US-20090264404-A1 Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-10-22 US disclosed
WO-2009081140-A1 METHOD TO DETERMINE LIPIDS AXIS-SHIELD ASA (NO) 2009-07-02 WO disclosed
US-7459465-B2 Isoquinoline compound and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-12-02 US disclosed
EP-1919907-A2 HETEROCYCLIC COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-05-14 EP disclosed
US-20070161620-A1 ISOQUINOLINE COMPOUND AND PHARMACEUTICAL USE THEREOF MITSUBISHI PHARMA CORPORATION (JP) 2007-07-12 US disclosed
WO-2007026959-A2 DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-03-08 WO disclosed
US-RE39199-E1 Antipsoriatic compositions, method of making, and method of using MOADY NASEBA 2006-07-18 US disclosed
US-5955081-A TREATMENT OF SKIN DISORDERS WITH PLANT EXTRACTS Z-92, INC. 1999-09-21 US disclosed
US-4650881-A ONE POT IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 1987-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10043981-B2 Light-emitting material, organic light-emitting device, and compound GRK1, ARL1, NR2E3 PTGES 2883/4885TYMP 4387/4885MAOA 2064/4885
US-20090264404-A1 Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders GRIN2C, GRIN2B, PMP22 PTGES 2661/4885TYMP 3933/4885MAOA 746/4885
US-20190071410-A1 3-Phenyl-7-Hydroxy-Isocoumarins as Macrophage Migration Inhibitory Factor (MIF) Inhibitors MIF, CCL2, MMP12 PTGES 193/4885TYMP 3409/4885MAOA 4106/4885
US-20070161620-A1 ISOQUINOLINE COMPOUND AND PHARMACEUTICAL USE THEREOF NQO1, PARP1, NUDT1 PTGES 2145/4885TYMP 631/4885MAOA 272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.